Population pharmacokinetics of cetuximab in patients with squamous cell carcinoma of the head and neck.
about
Population pharmacokinetic analysis of panitumumab in patients with advanced solid tumorsNonlinear pharmacokinetics of therapeutic proteins resulting from receptor mediated endocytosisA general process for the development of peptide-based immunoassays for monoclonal antibodies.Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2.Phase 1 study of anti-epidermal growth factor receptor monoclonal antibody in patients with solid tumors.Predicting the F(ab)-mediated effect of monoclonal antibodies in vivo by combining cell-level kinetic and pharmacokinetic modellingPopulation pharmacokinetic analysis of sifalimumab from a clinical phase IIb trial in systemic lupus erythematosus patientsCetuximab: its unique place in head and neck cancer treatmentPopulation pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's diseasePopulation pharmacokinetics of sifalimumab, an investigational anti-interferon-α monoclonal antibody, in systemic lupus erythematosus.Target-mediated drug disposition model: approximations, identifiability of model parameters and applications to the population pharmacokinetic-pharmacodynamic modeling of biologics.Population Pharmacokinetics of Necitumumab in Cancer Patients.Current status of treatment of metastatic colorectal cancer with special reference to cetuximab and elderly patients.Therapeutic monoclonal antibody concentration monitoring: free or total?Cetuximab in the treatment of squamous cell carcinoma of the head and neck.Biotherapeutic first-in-human dose selection: making use of preclinical markers.A guide to rational dosing of monoclonal antibodies.Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies.Bringing Model-Based Prediction to Oncology Clinical Practice: A Review of Pharmacometrics Principles and Applications.Potential Sources of Inter-Subject Variability in Monoclonal Antibody Pharmacokinetics.Drug Development of Therapeutic Monoclonal Antibodies.Optimization of radotinib doses for the treatment of Asian patients with chronic myelogenous leukemia based on dose-response relationship analyses.Semimechanistic model to characterize nonlinear pharmacokinetics of nimotuzumab in patients with advanced breast cancer.Model-based assessment of dosing strategies in children for monoclonal antibodies exhibiting target-mediated drug dispositionPopulation PK and IgE pharmacodynamic analysis of a fully human monoclonal antibody against IL4 receptor.Monoclonal antibody disposition: a simplified PBPK model and its implications for the derivation and interpretation of classical compartment models.Fixed dosing versus body size-based dosing of monoclonal antibodies in adult clinical trials.Use of a Target-Mediated Drug Disposition Model to Predict the Human Pharmacokinetics and Target Occupancy of GC1118, an Anti-epidermal Growth Factor Receptor Antibody.Potential of a Cetuximab-based radioimmunotherapy combined with external irradiation manifests in a 3-D cell assay.Clinical Pharmacokinetics and Pharmacodynamics of the Epidermal Growth Factor Receptor Inhibitor Panitumumab in the Treatment of Colorectal Cancer.
P2860
Q28257098-B58422B1-F569-4D7D-8536-570DA64B8916Q30489162-F9B4FD14-0EAA-4D3E-892B-4FEF23D494EBQ33525284-1A17D1BC-5355-411B-8C5A-4EE8F1DA59B8Q33710574-38F17E46-2489-4C53-9EBD-07F2950AF202Q34570074-CEC975D1-855B-4BDD-B0CC-45A1542D1C28Q35905876-5B45D7A9-4488-48C1-A405-48137C691B0EQ36806646-C5C67EA2-C852-4FA4-A87E-CB5A8A69245CQ36880604-FD4E0141-135E-422F-926A-2BE087C83162Q37275504-F3797F3F-047F-44C3-AB52-4E8A9BDA67A0Q37298794-272B123E-22E1-451C-BD98-AE5BC7E8F34EQ37510861-05BE56BA-9005-4D2A-A2D1-283E1F5F0D35Q37742626-44B7E555-E0EB-4625-8B0C-C3C228BC9D2FQ37771244-B93B6F93-4E7F-423B-8958-6B91FA0693BDQ37810218-98E03E94-4D9C-4675-8421-70E3CD0AD489Q37866779-7969576D-668F-434A-92C4-909DF6451076Q37960081-5B4BC1D4-3DC9-48D2-881B-9D39F0BD8F9BQ37976878-4403BD29-B703-4DB6-9848-AAA304ACA2AFQ38072598-B3F1F723-60EA-404E-9278-A338F9552860Q38289581-06554F27-4126-4392-8951-ED688580CA7BQ38714339-36CA9840-3298-4DCF-B9B2-C10B4202DC28Q38876360-433B3CFC-DF11-4B0C-811C-1C4F43150ED1Q40213114-672E9B3C-3DF6-4198-85CE-C6986EF51346Q41245735-175EE925-F8E8-448D-8358-B81192B3138DQ41915506-494A23BE-173A-4F52-8DB6-9413C6B544DCQ44699279-90B0FC96-E9D9-4D12-A5DB-BC169B75F199Q45347262-69AA2D5E-D99E-4CB6-A74B-B6DBF8A55270Q46427740-5E25BC9B-2ACF-40E2-B193-70CE5C943E8EQ50216230-8919F0BE-9B43-4AA3-924F-14D54382CF5CQ51749302-529088D3-BEC2-4ED5-B976-5B279D2F00D4Q55003485-97A40AAF-4903-48AD-AA0A-6129569682EA
P2860
Population pharmacokinetics of cetuximab in patients with squamous cell carcinoma of the head and neck.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Population pharmacokinetics of ...... arcinoma of the head and neck.
@en
Population pharmacokinetics of ...... arcinoma of the head and neck.
@nl
type
label
Population pharmacokinetics of ...... arcinoma of the head and neck.
@en
Population pharmacokinetics of ...... arcinoma of the head and neck.
@nl
prefLabel
Population pharmacokinetics of ...... arcinoma of the head and neck.
@en
Population pharmacokinetics of ...... arcinoma of the head and neck.
@nl
P2093
P2860
P356
P1476
Population pharmacokinetics of ...... arcinoma of the head and neck.
@en
P2093
Andreas Kovar
Arno Nolting
Nathanael L Dirks
P2860
P304
P356
10.1177/0091270007313393
P577
2008-01-24T00:00:00Z